36 results on '"Laskin, J."'
Search Results
2. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents
3. Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
4. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
5. Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer
6. Evaluation of a ‘Watch and Wait’ Approach for Chemotherapy in Patients with Newly Diagnosed Advanced Non-small Cell Lung Cancer from a Diverse Community Population
7. Adjuvant Chemotherapy in Resected Stage II Non-small Cell Lung Cancer: Evaluating the Impact of Dose Intensity and Time to Treatment
8. 87P Application of tissue and liquid-based next generation sequencing (NGS) for comprehensive genomic profiling: Evaluating the clinical value of ctDNA technology in treatment decision making
9. LBA4 Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
10. 2129P Feasibility of a virtual exercise program to mitigate decline in physical function for advanced lung cancer patients
11. LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
12. 1406P Outcomes of patients with metastatic EGFR mutant lung cancer requiring dose modifications of first line osimertinib
13. 1110P Clinical outcomes for EGFR/HER2 exon 20 insertion-mutated NSCLC
14. 960P Beyond PACIFIC: Real-world outcomes of adjuvant durvalumab according to treatment received and PD-L1 expression
15. 964P PACIFIC on the West Coast: Exploring reasons for not receiving consolidative durvalumab in the treatment of locally advanced lung cancer
16. 1195P The value of detecting resistance through liquid biopsy
17. 475O - Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)
18. P-291 - NRG1-fusion positive gastrointestinal tumours: afatinib as a novel potential treatment option
19. 466O - ASTRIS real world study of osimertinib in patients (pts) with EGFR T790M NSCLC: Efficacy analysis by tissue or plasma T790M test
20. 410P - FUS-NFATc2 sarcoma of bone, a novel molecular entity with aggressive behavior: Clinical and molecular pathology findings of two cases
21. 1583P - Patient reported stressors in the practical domain of a cancer diagnosis: The impact of socioeconomic status and geographic location
22. 585P - Clinical benefit of whole genome and transcriptome analysis (WGTA) in metastatic colorectal cancer (MCRC): Results from the personalized oncogenomics program (POG)
23. 2060 - Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)
24. LBA43 - Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)
25. 1519O - Availability of tumour gene expression data facilitates clinical decision-making for patients with advanced cancers
26. 1379P - Clinicians identify high need to increase their genomic literacy to applied cancer genomics
27. 1230P - Time-to-treatment failure (TTF) with first-line afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) advanced non-small-cell lung cancer (NSCLC): Randomized phase IIb LUX-lung 7 (LL7) trial
28. 1615P - Practical Guidelines for Ethical and Policy Issues that Arise from the Clinical Application of Whole Genome Sequencing in Cancer Patients
29. 1570O - Demonstration of Temporal Heterogeneity Identified By Genome Sequencing and the Potential Effect on Treatment Decisions for Advanced Cancer Patients
30. 1306P - Effective Knowledge Dissemination Improves Histological Classification of Non Small Cell Lung Cancer: Reducing the Rates of Nsclc – not Otherwise Specified (Nos)
31. 1277P - Prophylactic Treatment for Rash Induced By Egfr Inhibitor Improves Rash Without Compromising on Efficacy the Pancanadian Rash Trial: a Randomized Phase III Trial in Nsclc
32. 9171 Low incidence of grade 3 bleeding events and low discontinuation rates associated with first-line bevacizumab (Bev) in patients with advanced NSCLC: data from the SAiL (MO19390) study
33. 9168 Safety and efficacy of first-line bevacizumab-based therapy in advanced non-small cell lung cancer (NSCLC): results of the SAiL study (MO19390)
34. 9170 Safety and efficacy of first-line bevacizumab (Bv) plus chemotherapy in elderly patients (pts) with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): SAiL (MO19390)
35. 6594 POSTER First-line bevacizumab in combination with chemotherapy in the treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): an open-label safety study (MO19390)
36. 6548 POSTER Phase II study of sunitinib malate (SU) as consolidation therapy in patients (pts) with locally-advanced or metastatic non-small cell lung cancer (NSCLC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.